Are hepatocellular carcinoma patients more likely to receive liver resection in regions with longer transplant wait times?
- PMID: 24507051
- DOI: 10.1016/j.transproceed.2013.09.033
Are hepatocellular carcinoma patients more likely to receive liver resection in regions with longer transplant wait times?
Abstract
In areas with longer liver transplantation (LT) wait times, liver resection (LR) offers an appropriate alternative in selected patients with hepatocellular carcinoma (HCC). We identified adults with HCC undergoing LT or LR from the United States Nationwide Inpatient Sample from 1998-2008. United Network for Organ Sharing regions were assigned lower rank indicating shorter wait time for patients with Model for End-Stage Liver Disease (MELD) scores of 19-24 or ≥ 25. We used multivariate adjusted analysis to assess the odds of LR versus LT comparing patients by region. Of 4,516 patients, 40% received LT and 60% received LR. When ranked by wait times for MELD 19-24, the 3rd, 8th, and 11th ranked regions had decreased odds of LR versus LT (region 3: odds ratio [OR] 0.3, 95% confidence interval [CI] 0.2-0.6; region 8: OR 0.5, 95% CI 0.3-0.9; region 5: OR 0.3, 95% CI 0.2-0.6), whereas the 10th ranked region had increased odds (region 1: OR 1.9, 95% CI 1.1-3.4) compared with the region with the shortest wait time, region 10. When ranked by wait times for MELD ≥25, all regions except the 10th ranked region (region 5) had increased odds compared with the region with the shortest wait time, region 3 (OR 1.6-5.6; P < .001). Regional variations of LT versus LR are not completely explained by transplant wait times.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.Liver Transpl. 2016 Oct;22(10):1356-66. doi: 10.1002/lt.24507. Liver Transpl. 2016. PMID: 27348270
-
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.J Hepatol. 2014 Feb;60(2):290-7. doi: 10.1016/j.jhep.2013.10.010. Epub 2013 Oct 23. J Hepatol. 2014. PMID: 24161408
-
MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.Liver Transpl. 2015 May;21(5):612-22. doi: 10.1002/lt.24098. Epub 2015 Apr 15. Liver Transpl. 2015. PMID: 25694099
-
Current controversies surrounding liver transplantation for hepatocellular carcinoma.J Gastroenterol Hepatol. 2010 Jul;25(7):1217-26. doi: 10.1111/j.1440-1746.2010.06335.x. J Gastroenterol Hepatol. 2010. PMID: 20594247 Review.
-
Section 2. Small-for-size liver graft and hepatocellular carcinoma recurrence.Transplantation. 2014 Apr 27;97 Suppl 8:S7-S10. doi: 10.1097/01.tp.0000446266.42019.28. Transplantation. 2014. PMID: 24849840 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
